204 related articles for article (PubMed ID: 30114319)
1. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors.
Genç CG; Jilesen APJ; Nieveen van Dijkum EJM; Klümpen HJ; van Eijck CHJ; Drozdov I; Malczewska A; Kidd M; Modlin I
J Surg Oncol; 2018 Jul; 118(1):37-48. PubMed ID: 30114319
[TBL] [Abstract][Full Text] [Related]
2. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies.
Modlin IM; Frilling A; Salem RR; Alaimo D; Drymousis P; Wasan HS; Callahan S; Faiz O; Weng L; Teixeira N; Bodei L; Drozdov I; Kidd M
Surgery; 2016 Jan; 159(1):336-47. PubMed ID: 26456125
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
4. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
[TBL] [Abstract][Full Text] [Related]
5. Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy.
Modlin IM; Kidd M; Frilling A; Falconi M; Filosso PL; Malczewska A; Kitz A
Ann Surg; 2021 Sep; 274(3):481-490. PubMed ID: 34183517
[TBL] [Abstract][Full Text] [Related]
6. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
[TBL] [Abstract][Full Text] [Related]
7. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.
Modlin IM; Kidd M; Falconi M; Filosso PL; Frilling A; Malczewska A; Toumpanakis C; Valk G; Pacak K; Bodei L; Öberg KE
Ann Oncol; 2021 Nov; 32(11):1425-1433. PubMed ID: 34390828
[TBL] [Abstract][Full Text] [Related]
8. Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors.
Partelli S; Andreasi V; Muffatti F; Schiavo Lena M; Falconi M
Ann Surg Oncol; 2020 Oct; 27(10):3928-3936. PubMed ID: 32253675
[TBL] [Abstract][Full Text] [Related]
9. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
10. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
[TBL] [Abstract][Full Text] [Related]
11. Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas: A potential predictor of postoperative recurrence.
Nanno Y; Toyama H; Matsumoto I; Otani K; Asari S; Goto T; Ajiki T; Zen Y; Fukumoto T; Ku Y
Pancreatology; 2017; 17(2):291-294. PubMed ID: 28043759
[TBL] [Abstract][Full Text] [Related]
12. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.
Jilesen AP; Busch OR; van Gulik TM; Gouma DJ; Nieveen van Dijkum EJ
Dig Surg; 2014; 31(6):407-14. PubMed ID: 25572908
[TBL] [Abstract][Full Text] [Related]
13. Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest).
Modlin IM; Kidd M; Oberg K; Falconi M; Filosso PL; Frilling A; Malczewska A; Salem R; Toumpanakis C; Laskaratos FM; Partelli S; Roffinella M; von Arx C; Kudla BK; Bodei L; Drozdov IA; Kitz A
Ann Surg Oncol; 2021 Nov; 28(12):7506-7517. PubMed ID: 34008138
[TBL] [Abstract][Full Text] [Related]
14. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
15. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
[TBL] [Abstract][Full Text] [Related]
16. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
[TBL] [Abstract][Full Text] [Related]
17. The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression.
Filosso PL; Kidd M; Roffinella M; Lewczuk A; Chung KM; Kolasinska-Cwikla A; Cwikla J; Lowczak A; Doboszynska A; Malczewska A; Catalano M; Zunino V; Boita M; Arvat E; Cristofori R; Guerrera F; Oliaro A; Tesselaar M; Buikhuisen W; Kos-Kudla B; Papotti M; Bodei L; Drozdov I; Modlin I
Eur J Cardiothorac Surg; 2018 Mar; 53(3):631-639. PubMed ID: 29145657
[TBL] [Abstract][Full Text] [Related]
18. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
20. The impact of surgery for metastatic pancreatic neuroendocrine tumor: a contemporary evaluation matching for chromogranin a level.
Concors SJ; Sinnamon AJ; Ecker BL; Metz DC; Vollmer CM; Fraker DL; Roses RE
HPB (Oxford); 2020 Jan; 22(1):83-90. PubMed ID: 31239188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]